Interní Med. 2012; 14(4): 173-176
The perioperative management of patients treated with warfarin should be based on the evaluation of the individual risk of thrombotic
complications and bleeding. The patients undergoing procedures associated with low risk of major bleeding (dental procedures, cataract
surgery, etc.) don‘t need any alteration of the anticoagulation; it’s however prudent to ascertain the INR seven days and one day prior to
the procedure to avoid the overanticoagulation. In patients undergoing all other invasive procedures the therapy with warfarin should
be stopped; bridging with low molecular weight heparin is required in some of them. The inherent risk of venous or arterial thromboembolism
is related to the underlying condition (reason for the anticoagulation). The risk of venous thromboembolism is in addition
increased by the surgery (postoperative risk). Preoperatively, the strategy is determined by the inherent risk of thrombosis. The therapy
with warfarin should be interrupted 5 days prior to the procedure. If the INR 1 day before surgery is ≥ 1.5, administering 1–2 mg of oral
vitamin K is suggested. In patients with low inherent risk no preoperative pharmacological thromboprophylaxis is needed. In patients
with high inherent risk (recent, idiopathic, recurrent, or paraneoplastic venous thromboembolism, mechanical heart valve prosthesis,
intermediate and high-risk atrial fibrillation) full dose of LMWH should be started immediately as the INR falls below 2.0. Therapy with
LMWH should be stopped 24 hours before surgery. In patients with intermediate inherent risk (provoked venous thromboembolism
older, than 6 weeks) prophylactic dose of LMWH should be started as the INR falls below 2.0; the last prophylactic dose should be administered
approximately 12 hours before surgery. The postoperative management is determined by the postoperative risk adjusted
according to the inherent risk and to the risk of bleeding. The prophylactic dose of LMWH is restarted usually 6–12 h post procedure,
when the haemostasis is secured. In patients with high inherent risk of venous thromboembolism and in patients with intermediate or
high risk of arterial thromboembolism the dose of LMWH should be increased to the therapeutic dose 48–72 hours after the end of the
surgery, if the haemostasis is secured. Warfarin is usually restarted in the evening of the day of procedure, or in the 1st postoperative day.
In patients requiring urgent surgery, the reversal of the effect of warfarin is necessary, if the INR is ≥ 1.5; the administration of low-dose
vitamin K (5 mg) orally or intravenously is recommended for them. For more immediate reversal of the anticoagulant effect treatment
with prothrombin concentrate is recommended (especially in patients requiring the surgery within ≤ 12 hours).
Published: April 23, 2012 Show citation